HC Wainwright Forecasts Weaker Earnings for Immix Biopharma

Immix Biopharma, Inc. (NASDAQ:IMMX) – Research analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for shares of Immix Biopharma in a report issued on Monday, January 6th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.87) per share for the year, down from their previous estimate of ($0.67). HC Wainwright currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Immix Biopharma’s current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Immix Biopharma’s Q4 2024 earnings at ($0.25) EPS, Q1 2025 earnings at ($0.23) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.85) EPS.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.08).

Immix Biopharma Stock Performance

Shares of NASDAQ IMMX opened at $2.10 on Thursday. The stock has a market cap of $57.77 million, a price-to-earnings ratio of -2.47 and a beta of 0.27. The business has a 50 day simple moving average of $2.03 and a 200 day simple moving average of $1.95. Immix Biopharma has a 52 week low of $1.26 and a 52 week high of $6.33.

Institutional Investors Weigh In On Immix Biopharma

A hedge fund recently bought a new stake in Immix Biopharma stock. Invst LLC purchased a new stake in Immix Biopharma, Inc. (NASDAQ:IMMX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 27,000 shares of the company’s stock, valued at approximately $57,000. Invst LLC owned approximately 0.10% of Immix Biopharma as of its most recent filing with the SEC. Institutional investors own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.